T1	Disorder 10 17	Colitis
N1 	Reference T1 UMLS:C0009319	Colitis
T2	Pharmacological_substance 40 50	infliximab
N1000 	Reference T2 MeSH:D000069285	infliximab
T3	Disorder 62 89	disseminated cryptococcosis
N2 	Reference T3 UMLS:C0276687	disseminated cryptococcosis
T6	Disorder 235 262	disseminated cryptococcosis
N3 	Reference T6 UMLS:C0276687	disseminated cryptococcosis
T7	Disorder 335 350	yeast infection
N4 	Reference T7 UMLS:C0276680	yeast infection
N5 	Reference T7 UMLS:C0276680	yeast infection
T8	Disorder 381 408	disseminated cryptococcosis
N6 	Reference T8 UMLS:C0276687	disseminated cryptococcosis
T9	Disorder 423 430	colitis
N7 	Reference T9 UMLS:C0009319	colitis
T10	Disorder 464 479	Crohn's disease
N8 	Reference T10 UMLS:C0010346	Crohn's disease
T11	Pharmacological_substance 485 504	TNF-alpha inhibitor
T14	Disorder 588 605	GI cryptococcosis
T15	Disorder 631 658	disseminated cryptococcosis
N9 	Reference T15 UMLS:C0276687	disseminated cryptococcosis
T16	Disorder 754 778	opportunistic infections
N10 	Reference T16 UMLS:C0029118	opportunistic infections
T17	Pharmacological_substance 799 819	TNF-alpha inhibitors
T20	Disorder 912 942	immune reconstitution syndrome
N11 	Reference T20 UMLS:C1096197	immune reconstitution syndrome
T5	Disorder 264 299	Gastrointestinal (GI) tract disease
T21	Disorder 560 577	immunocompromised
N12 	Reference T21 UMLS:C0085393	immunocompromised
T22	Subject 578 586	patients
T23	Pharmacological_substance 107 151	tumor necrosis factor (TNF)-alpha inhibitors
T24	Disorder 850 889	rapid rebound of inflammatory responses
T32	Speculation_cue 201 204	may
